Renner André, Zittermann Armin, Aboud Anas, Hakim-Meibodi Kavous, Börgermann Jochen, Gummert Jan F
Clinic for Thoracic and Cardiovascular Surgery, Heart Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany
Clinic for Thoracic and Cardiovascular Surgery, Heart Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany.
Interact Cardiovasc Thorac Surg. 2015 Jan;20(1):85-9. doi: 10.1093/icvts/ivu337. Epub 2014 Oct 15.
Data regarding durability and midterm benefits of mitral valve (MV) repair in elderly patients are scarce. To evaluate the feasibility and safety of MV repair in elderly patients, we performed a retrospective data analysis.
We compared clinical outcomes in younger patients (<75 years: n = 462) and older patients (≥75 years: n = 100) undergoing MV repair with or without tricuspid valve (TV) repair. The primary end-point was 30-day mortality.
The preoperative risk profile (EuroSCORE, NYHA class, percentage pulmonary hypertension, percentage diabetes) was higher in older patients compared with younger patients. Nevertheless, operative complications such as low cardiac output syndrome, stroke, infections, the need of haemofiltration and IABP use did not differ significantly between the two groups. The thirty-day mortality rate was 0% in older patients and 1% in younger patients (P = 0.30). In the subgroup of patients with double valve repair, the 30-day mortality rate in older patients (n = 28) and younger patients (n = 46) was 0 and 4%, respectively (P = 0.27). In older and younger patients, the 6-month mortality rate was 4 and 2%, respectively (P = 0.16), and the 1-year mortality rate was 10 and 3%, respectively (P = 0.001). The propensity score-adjusted odds ratio of 1-year mortality with the group of younger patients as a reference was 2.04 (95% confidence interval: 0.77-5.40; P = 0.15) for older patients. Freedom from 1-year reoperation did not differ significantly between age groups.
Data demonstrate excellent postoperative mortality rates in older patients undergoing MV repair with or without TV repair. Consequently, even in older patients with numerous comorbidities, MV repair should be considered a suitable surgical method.
关于老年患者二尖瓣(MV)修复的耐久性和中期益处的数据稀缺。为了评估老年患者MV修复的可行性和安全性,我们进行了一项回顾性数据分析。
我们比较了接受或未接受三尖瓣(TV)修复的MV修复的年轻患者(<75岁:n = 462)和老年患者(≥75岁:n = 100)的临床结果。主要终点是30天死亡率。
与年轻患者相比,老年患者的术前风险特征(欧洲心脏手术风险评估系统评分、纽约心脏协会心功能分级、肺动脉高压百分比、糖尿病百分比)更高。然而,两组之间的心输出量低综合征、中风、感染、血液滤过需求和主动脉内球囊反搏使用等手术并发症并无显著差异。老年患者的30天死亡率为0%,年轻患者为1%(P = 0.30)。在双瓣膜修复患者亚组中,老年患者(n = 28)和年轻患者(n = 46)的30天死亡率分别为0%和4%(P = 0.27)。老年和年轻患者的6个月死亡率分别为4%和2%(P = 0.16),1年死亡率分别为10%和3%(P = 0.001)。以年轻患者组为参照,老年患者1年死亡率的倾向评分调整比值比为2.04(95%置信区间:0.77 - 5.40;P = 0.15)。各年龄组之间1年再次手术率无显著差异。
数据表明,接受或未接受TV修复的老年患者MV修复术后死亡率极低。因此,即使是患有多种合并症的老年患者,MV修复也应被视为一种合适的手术方法。